Eli Lilly and Co (LLY) delivered a robust performance in its Q3 2025 earnings report, surpassing analyst expectations. The company reported earnings per share (EPS) of $7.02, significantly outpacing the consensus estimate of $5.75 by $1.27. Revenue also exceeded forecasts, coming in at $17.6 billion, compared to the anticipated $16.2 billion.
This strong financial showing underscores Eli Lilly's solid operational performance and financial health. Investors will have the opportunity to gain further insights during the upcoming earnings conference call, where management will discuss these results and provide additional context on the company's business performance.
As a leader in the pharmaceutical industry, Eli Lilly engages in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products. The company, headquartered in Indianapolis, Indiana, employs approximately 47,000 full-time staff. Its diverse portfolio includes cardiometabolic health products, oncology treatments, immunology solutions, and neuroscience products. Eli Lilly is also advancing innovative therapies through its subsidiary, POINT Biopharma Global Inc.
Looking ahead, the company is set to report its next earnings on August 4, 2026, with EPS estimated at $7.7023 and revenue projected at $17.9 billion. This update provides insight into Eli Lilly and Co's ongoing commitment to delivering strong results in the competitive pharmaceutical landscape.